Baltimore-Based CSA Medical Raises $20.5 Million in Second Round
Baltimore — CSA Medical, the Baltimore-based developer of a spray cryotherapy device that freeze and destroy unwanted tissue inside the body, said on Thursday it has raised $20.5 million in its second round of funding, co-led by Intersouth Partners and First Analysis. Other investors in the round included S.V. Life Sciences, Rose Park, and Blue Heron Capital. The company will use the proceeds to fund post-market clinical studies and ongoing development activities. “This partnership and funding will support the launch of our new platform, expanded utilization and further development of new clinical applications,” said CEO Bill Floyd. CSA’s technology is currently being used at more than 80 cancer centers and academic teaching hospitals to treat esophageal disease.